Efficacy and safety of PD-1/PD-L1 inhibitors combined with anti-angiogenic therapy for the unresectable hepatocellular carcinoma and the benefit for hepatitis B virus etiology subgroup: a systematic review and meta-analysis of randomized controlled trials

BACKGROUND: Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death, worldwide. The predominant causative factor for HCC is hepatitis B virus (HBV) infection. We conducted a meta-analysis to estimate the efficacy and safety of PD-1/PD-L1 inhibitors combined with anti-angiog...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Danxue, Ke, Liyuan, Cui, Hongxia, Li, Su
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207853/
https://www.ncbi.nlm.nih.gov/pubmed/37226111
http://dx.doi.org/10.1186/s12885-023-10960-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207853/
https://www.ncbi.nlm.nih.gov/pubmed/37226111
http://dx.doi.org/10.1186/s12885-023-10960-w

Ejemplares similares